Balancing Benefits and Risks of Melanoma Treatment: What Do We Tell Our Patients?October 15th 2013
All of us treating patients with melanoma must educate our patients about the importance of participating in clinical trials with these new agents so that we can systematically validate the benefits and risks of these agents in prospectively defined patient settings.
An Argument for Aggressive Resection in MelanomaOctober 15th 2013
Any minimization of therapy in the name of reducing morbidity requires careful consideration. Reducing morbidity in melanoma is certainly a laudable goal, but locoregional disease control and cure must remain our primary objectives.
Cancer Care and Accountable Care Organizations: The Unknown Patient Experience LandscapeOctober 15th 2013
ACOs can provide the structure, but it’s up to the stakeholders to establish mutually agreeable goals for this new care delivery model. Achieving these goals will require a different set of dialogues and conversations among stakeholders, and patients and their advocates must have seats at the table.
The ‘Watch-and-Wait’ Approach for Rectal Cancer: Are Outcomes Improved With More Limited T Stage and Routine Use of MRI for Staging?October 15th 2013
We also propose that limiting the watch-and-wait strategy to patients with T1/T2N0 rectal cancer and using adequate T staging with MRI will result in improvements in local control and patient outcomes.
The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic ChemotherapyOctober 15th 2013
A 55-year-old woman with a history of metastatic melanoma in remission for 8 years presented to the emergency department with gross hematuria. A CT scan, ordered because the patient was in menopause, demonstrated a bladder tumor.
Multimodality Therapy for High-Risk Endometrial Cancer: Balancing the Courses While Keeping All Options on the TableOctober 15th 2013
As advances in treatment strategies continue to focus on individualization of therapy, the identification of disease subsets is crucial to strategizing optimal therapeutic approaches.
PSA Screening: Good Evidence Shows Little Benefit, Significant HarmsOctober 15th 2013
The Task Force’s recommendation against PSA screening for prostate cancer is based on the best available science and the knowledge that, while we all want to prevent suffering and death from prostate cancer, PSA screening simply does not get us there.
PSA Screening in Men Newly Diagnosed With Colorectal Cancer: Each According to His Group’s Means?October 15th 2013
Once a patient has been appropriately educated by an informed healthcare provider about the possible benefits of PSA screening, then patient preference as part of shared decision making regarding PSA screening should be considered in all cases.
PSA Screening for Colorectal Cancer Patients: Proceeding With CautionOctober 15th 2013
It may be appropriate to offer prostate cancer screening to carefully selected men with a previous history of colorectal cancer. However, the risks and benefits of establishing the diagnosis in this setting need to be considered and discussed with them.
Should All Colorectal Cancer Patients Over Age 60 Be Screened for Prostate Cancer?October 15th 2013
Not all patients with colorectal cancer are candidates for such screening, however, as a remaining life expectancy of at least 10 years is generally required in order for PSA screening to yield a significant mortality benefit.
The Value of Pelvic Radiation Therapy After Hysterectomy for Early Endometrial CancerOctober 15th 2013
In this review, the results and limitations of studies concerning adjuvant radiation therapy and chemotherapy for endometrial cancer will be discussed, focusing on evidence that can help to guide treatment decisions.
Pelvic Radiation Therapy for Early Endometrial Cancer: Careful Selection Is KeyOctober 15th 2013
Future directions, including nomograms, multi-modality approaches, and more individualized patient care based on genomic profiles, may help to tailor each endometrial cancer patient’s therapy to her individual risk.